Treatment of tardive dyskinesia

Schizophrenia Bulletin

Volumn 23, Issue 4, 1997, Pages 583-609

  Egan, Michael F ^a   Apud, Jose ^b   Wyatt, Richard Jed ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CLONIDINE; CLOZAPINE; HALOPERIDOL; LEVODOPA; METHYLDOPA; METIROSINE; MOLINDONE; OLANZAPINE; QUETIAPINE; SERTINDOLE; ZIPRASIDONE;

DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; TARDIVE DYSKINESIA;

EID: 0030712881     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/23.4.583     Document Type: Review

References (255)

1. Abad, V., and Ovsiew, F. Treatment of persistent myoclonic tardive dystonia with verapamil. British Journal of Psychiatry, 162:554-556, 1993.
2. Adler, L.; Duncan, E.; Reiter, S.; Angrist, B.; Peselow, E.; and Rotrosen, J. Effects of calcium channel antagonists on tardive dyskinesia and psychosis. Psychopharmacology Bulletin, 24(3):421-425, 1988.
3. Adler, L.; Peselow, E.; Rotrosen, J.; Duncan, E.; Lee, M.; Rosenthal, M.; and Angrist, B. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatry, 150:1405-1407, 1993.
4. Aktar, S.; Jajor, T.R.; and Kumar, S. Vitamin E in the treatment of tardive dyskinesia. Journal of Postgraduate Medicine, 39:124-126, 1993.
5. Albin, R.L.; Young, A.B.; and Penney, J.B. The functional neuroanatomy of the basal ganglia disorders. Trends in Neuroscience, 12:366-375, 1989.
6. American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive Dyskinesia - A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press, 1992.
7. Anderson, U.; Haggstrom, J.E.; Bondessan, U.; Valverius, M.; and Gunne, L.M. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Movement Disorders, 4:37-46, 1989.
8. Andreassen, O.A., and Jorgensen, H.A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology, 116(4):517-522, 1994.
9. Arya, D.K., and Szabadi, E. Dyskinesia associated with fluvoxamine. [Letter] Journal of Clinical Psychopharmacology, 13(5):365-366, 1993.
10. Baldessarini, R.J.; Cole, J.O.; and Davis, J.M. Tardive Dyskinesia: A Task Force Report. Washington, DC: American Psychiatric Association, 1980.
11. Baldessarini, R.J., and Davis, J.M. What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Research, 3:115-122, 1980.
12. Baldessarini, R.J., and Marsh, E. Fluoxetine and side effects. [Letter] American Journal of Psychiatry, 147:191-192, 1990.
13. Barnes, T.R.E.; Kidger, T.; and Gore, S.M. Tardive dyskinesia: A 3-year follow up study. Psychological Medicine, 13:71-81, 1983.
14. Barnes, T.R.E., and Wiles, D.H. Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment. Psychopharmacology, 81:359-362, 1983.
15. Barrow, N., and Childs, A. An anti-tardive dyskinesia effect of verapamil. [Letter] American Journal of Psychiatry, 143:1485, 1986.
16. Beasley, C.M., Jr.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T.; and Hamilton, S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14:111-123, 1996.
17. Benecke, R.; Conrad, B.; and Klingelhofer, J. Successful treatment of tardive and spontaneous dyskinesias with corticosteroids. European Neurology, 28:146-149, 1988.
18. Bergen, J.A.; Eyland, E.A.; Campbell, J.A.; Jenkings, P.; Kellejear, K.; Richards, A.; and Beumont, P.J.V. The course of tardive dyskinesia in patients on long-term neuroleptics. British Journal of Psychiatry, 154:523-528, 1989.
19. Bergen, J.A.; Kitchin, R.; and Berry, G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biological Psychiatry, 32:580-594, 1992.
20. Blum, I.; Munitz, H.; Shalev, A.; and Roberts, E. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clinical Neuropharmacology, 7(3):265-267, 1984.
21. Borison, R.L.; Arvantis, L.A.; and Miller, B.G. A comparison of five fixed doses of "Seroquel" (ICI-204,636) with haloperidol and placebo in patients with schizophrenia. [Abstract] Schizophrenia Research, 18:132, 1996.
22. Bouchard, R.H.; Pourcher, E.; and Vincent, P. Fluoxetine and extrapyramidal side effects. [Letter] American Journal of Psychiatry, 146:1352-1353, 1989.
23. 2 agonists in MPTP-treated primates: Functional implications for Parkinson's disease. Neurology, 40:927-933, 1990.
24. Boylan, K. Persistent dystonia associated with buspirone. [Letter] Neurology, 40:1904, 1990.
25. Braun, A.; Fabbrini, G.; Nouradian, M.M.; Serrati, C.; Barone, P.; and Chase, T.N. Selective D-1 receptor agonist treatment of Parkinson's disease. Journal of Neural Transmission, 68:41-50, 1987.
26. Braun, V., and Richter, H.P. Selective peripheral denervation for the treatment of spasmodic torticollis. Neurosurgery, 35:58-62, 1994.
27. Brody, D.; Adler, K.A.; Kime, T.; Angrist, B.; and Rotrosen, J. Effects of buspirone in seven schizophrenic subjects. Journal of Clinical Psychopharmacology, 10:68-69, 1990.
28. Browne, J.; Silver, H.; Martin, R.; Hart, R.; Mergener, M.; and Williams, P. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia. Journal of Clinical Psychopharmacology, 6:88-92, 1986.
29. 2 receptor blockade by flunarizine and cinnarizine explains EPS side effects: A SPECT study. Journal of Cerebral Blood Flow and Metabolism, 15:513-518, 1995.
30. Buck, O.D., and Harvey, P. Treatment of tardive dyskinesia with verapamil. Journal of Clinical Psychopharmacology, 8:303-304, 1988.
31. Budman, C.L., and Bruun, R.D. Persistent dyskinesia in a patient receiving fluoxetine. [Letter] American Journal of Psychiatry, 148:1403, 1991.
32. Burke, R.E.; Fahn, S.; Jankovic, J.; Marsden, C.D.; Lang, A.E.; Gollomp, S.; and Ilson, J. Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs. Neurology, 32:1335-1346, 1982.
33. Buzan, R.D. Risperidone-induced tardive dyskinesia. American Journal of Psychiatry, 153:734-735, 1996.
34. Caine, E.D.; Polinsky, R.J.; Kartzinel, R.; and Ebert, M.H. The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry, 136:317-320, 1979.
35. Carpenter, W.T., Jr.; Hanlon, T.E.; Heinrichs, D.W.; Summerfelt, A.T.; Kirkpatrick, B.; Levine, J.; and Buchanan, R.W. Continuous versus targeted medication in schizophrenic outpatients: Outcome results. American Journal of Psychiatry, 147:1138-1148, 1990.
36. Carroll, B.J.; Curtiss, C.G.; and Kokmen, E. Paradoxical response to dopamine agonists in tardive dyskinesia. American Journal of Psychiatry, 134:785-790, 1977.
37. Casey, D.E. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacology Bulletin, 25(3):457-459, 1989.
38. Casey, D.E. Behavioral effects of sertindole, risperidone, clozapine, and haloperidol in Cebus monkeys. Psychopharmacology, 124(1-2):134-140, 1996.
39. Casey, D.E., and Gerlach, J. Tardive dyskinesia: What is the long-term outcome? In: Casey, D.E., and Gerlach, J., eds. Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. Washington, DC: American Psychiatric Press, 1986. pp. 75-97.
40. Casey, D.E., and Hansen, T.E. Spontaneous dyskinesia. In: Jeste, D.V., and Wyatt, R.J., eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Press, 1984. pp. 68-95.
41. Casey, D.E., and Rabins, P. Tardive dyskinesia as a life-threatening illness. American Journal of Psychiatry, 135:486-488, 1978.
42. Chakos, M.H.; Alvir, J.M.; Woerner, M.G.; Koreen, A.; Geisler, S.; Mayerhoff, D.; Sobel, S.; Kane, J.M.; Borenstein, M.; and Lieberman, J.A. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 53(4):313-319, 1996.
43. Chiu, H.F.K.; Lee, S.; and Chan, C.H.S. Misdiagnosis of respiratory dyskinesia. Acta Psychiatrica Scandinavica, 83:494-495, 1991.
44. Chouinard, G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. Journal of Clinical Psychopharmacology, 15(Suppl. 1):36-44, 1995.
45. Chouinard, G.; Annable, L.; Rose-Chouinard, A.; and Mercier, P. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. Journal of Clinical Psychopharmacology, 8(Suppl.):21-26, 1988.
46. Christensen, E.; Moller, J.E.; and Faurbye, A. Neuropathological investigation of 28 brains from patients with dyskinesias. Acta Psychiatrica Scandinavica, 46:14-23, 1970.
47. Cole, J.O.; Gardos, G.; and Rapkin, R.M. Lithium carbonate in tardive dyskinesia and schizophrenia. In: Gardos, G., and Casey, D.E., eds. Dyskinesia and Affective Disorder. Washington, DC: American Psychiatric Press, 1984. pp. 49-73.
48. Cole, J.O.; Gardos, G.; and Tarsy, D. Drug trials in persistent dyskinesia. In: Fann, W.E.; Smith, R.C.; and Davis, J.M., eds. Tardive Dyskinesia, Research and Treatment. New York, NY: SP Medical and Scientific Books, 1980. pp. 419-427.
49. Colon, R.J. Long-lasting changes in cerebral neurons induced by drugs. Biological Psychiatry, 10:227, 1975.
50. Coupland, N., and Nutt, D. Successful treatment of tardive oculogyric spasms with vitamin E. [Letter] Journal of Clinical Psychopharmacology, 15:285-286, 1995.
51. Crossman, A.E. A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment. Movement Disorders, 5:100-108, 1990.
52. Curran, J.P. Management of tardive dyskinesia with thiopropazate. American Journal of Psychiatry, 130:925-927, 1973.
53. Dabiri, L.M.; Pasta, D.; Darby, J.K.; and Mosbacher, D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. American Journal of Psychiatry, 151:925-926, 1994.
54. Daniel, D.G.; Smith, K.; Hyde, T.; and Egan, M. Neuroleptic-induced tardive dyskinesia. [Letter] American Journal of Psychiatry, 153:734, 1996.
55. Delay, J., and Deniker, P. Trente-huit cas de psychoses traites par la cure prolongee et continue de 4568 R. Annales Medico-Psychologiques, 110:364, 1952.
56. DeLong, M.R. Primate models of movement disorders of basal ganglia origin. Trends in Neuroscience, 13:281-289, 1990.
57. Dixon, L.; Thaker, G.; Conley, R.; Ross, D.; Cascella, N.; and Tamminga, C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophrenia Research, 10:267-271, 1993.
58. Doongaji, D.R.; Jeste, D.V.; Jape, N.M.; Sheth, A.S.; Apte, J.S.; Vahia, V.N.; Desai, A.B.; Parkih, M.D.; Rathi, L.G.; Ghandi, M.H.; Parikh, R.M.; Thatte, S.; and Bharadwaj, J. Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. Journal of Clinical Psychopharmacology, 2:376-379, 1982.
59. Duncan, E.; Adler, L.; Angrist, B.; and Rotrosen, J. Nifedipine in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology, 10:414-416, 1990.
60. 2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse, 18:178-189, 1994.
61. Egan, M.F.; Hyde, T.M.; Albers, G.W.; Elkashef, A.; Alexander, R.C.; Reeve, A.; Blum, A.; Saenz, R.E.; and Wyatt, R.J. Treatment of tardive dyskinesia with vitamin E. American Journal of Psychiatry, 149:773-777, 1992.
62. Elkashef, A.M.; Ruskin, P.E.; Bacher, N.; and Barrett, D. Vitamin E in the treatment of tardive dyskinesia. American Journal of Psychiatry, 147:505-506, 1990.
63. Fahn, S. High-dose anticholinergic therapy in dystonia. Neurology, 33:1255-1261, 1983.
64. Fahn, S. A therapeutic approach to tardive dyskinesia. Journal of Clinical Psychiatry, 464:19-24, 1985.
65. Falk, W.E.; Wojcik, J.D.; and Gelenberg, A.J. Diltiazem for tardive dyskinesia and tardive dystonia. Lancet, 1:824-825, 1988.
66. Fenton, W.S.; Wyatt, R.J.; and McGlashan, T.H. Risk factors for spontaneous dyskinesia in schizophrenia. Archives of General Psychiatry, 51(8):643-650, 1994.
67. Fibiger, H.C., and Lloyd, K.G. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis. Trends in Neuroscience, 12:462-464, 1989.
68. Fisk, G.G., and York, S.M. The effect of sodium valproate on tardive dyskinesia - Revisited. British Journal of Psychiatry, 150:542-546, 1987.
69. Fleischhacker, W.W.; Linkz, C.G.G.; and Hurst, B.C. ICI-204,636 ("Seroquel") - A putative new atypical antipsychotic: Results from phase III trials. [Abstract] Schizophrenia Research, 18:132, 1996.
70. Fog, R.; Pakkenberg, H.; Jaul, P.; Bock, E.; Jorgensen, O.; and Anderssen, J. High dose treatment of rats with perphenazine enanthate. Psychopharmacology, 50:3305-3307, 1976.
71. Frangos, E., and Christodoulides, H. Clinical observations on the treatment of tardive dyskinesia with haloperidol. Acta Psychiatrica Belgica, 75:19-32, 1975.
72. Freedman, R.; Kirch, D.; Bell, J.; Adler, L.E.; Peceivich, M.; Patchman, E.; and Denver, P. Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatrica Scandinavica, 65:35-45, 1982.
73. Friedman, J.H. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Movement Disorders, 9:321-324, 1994.
74. Friis, T.; Christensen, T.R.; and Gerlach, J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism, and hyperkinesia. Acta Psychiatrica Scandinavica, 67:178-187, 1983.
75. Gale, K. Chronic blockade of dopamine receptors by anti-schizophrenic drug enhances GABA binding in substantia nigra. Nature, 283:569-570, 1980.
76. Gardos, G.; Casey, D.E.; Cole, J.O.; Perenyi, A.; Kocsis, E.; Arato, M.; Samson, J.A.; and Conley, C. Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry, 151:836-841, 1994.
77. Gardos, G., and Cole, J.O. Pilot study of cyproheptadine (Periactin) in tardive dyskinesia. Psychopharmacology Bulletin, 14(1):18-20, 1978.
78. Gardos, G., and Cole, J.O. The prognosis of tardive dyskinesia. Journal of Clinical Psychiatry, 44:177-179, 1983.
79. Gardos, G., and Cole, J.O. The treatment of tardive dyskinesia. In: Bloom, F.E., and Kupfer, D.J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995. pp. 1503-1511.
80. Gardos, G.; Cole, J.O.; Rapkin, R.M.; LaBrie, R.A.; Baquelod, E.; Moore, P.; Sovner, R.; and Doyle, J. Anticholinergic challenge and neuroleptic withdrawal. Archives of General Psychiatry, 41:1030-1035, 1984.
81. Gardos, G.; Cole, J.O.; Salomon, M.; and Schienbolk, S. Clinical forms of severe tardive dyskinesia. American Journal of Psychiatry, 144:895-902, 1987.
82. Gardos, G.; Perenyi, A.; Cole, J.O.; Samu, I.; Kocsis, E.; and Casey, D.E. Seven-year follow up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology, 1:169-172, 1988.
83. Gattaz, W.F.; Emrich, A.; and Behrens, S. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: Possible implications for tardive dyskinesia. Journal of Neural Transmission, 92:197-201, 1993.
84. Gerbino, L.; Shopsin, B.; and Collora, M. Clozapine in the treatment of tardive dyskinesia: An interim report. In: Fann, W.E.; Smith, R.C.; and Davis, J.M., eds. Tardive Dyskinesia: Research and Treatment. New York, NY: SP Medical and Scientific Books, 1980. pp. 475-489.
85. Gerlach, J. Long-term effects of perphenazine on the substantia nigra in rats. Psychopharmacologia, 45:51, 1975.
86. Gerlach, J., and Casey, D.E. Sulpiride in tardive dyskinesia. Acta Psychiatrica Scandinavica, 311(Suppl. 69):93-101, 1983.
87. Gerlach, J., and Casey, D.E. Tardive dyskinesia. Acta Psychiatrica Scandinavica, 77:369-378, 1988.
88. Gerlach, J.; Koppelhaus, P.; and Helweg, E. Clozapine and haloperidol in a single-blind crossover trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatrica Scandinavica, 50:410-424, 1974.
89. Gerlach, J.; Rye, T.; and Kristjansen, P. Effect of baclofen on tardive dyskinesia. Psychopharmacology, 56(2):145-151, 1978.
90. Gerlach, J., and Simmelsgaard, H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology, 59:105-112, 1978.
91. Ghadirian, A.M.; Annable, L.; Belanger, M.C.; and Chouinard, G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Journal of Clinical Psychiatry, 57(1):22-28, 1996.
92. Gibson, A. Depot injections and tardive dyskinesia. British Journal of Psychiatry, 132:361-365, 1978.
93. Gilbert, P.L.; Harris, J.; McAdam, L.A.; and Jeste, D.V. Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52:173-188, 1995.
94. Glazer, W.M.; Bowers, M.B.; Charney, D.S.; and Heninger, G.R. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biological Psychiatry, 26:224-233, 1989.
95. Glazer, W.M., and Hafez, H.M. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research, 3:315-320, 1990.
96. Glazer, W.M.; Hafez, H.M.; and Benarroche, L.L. Molindone and halperidol in tardive dyskinesia. Journal of Clinical Psychiatry, 46:4-7, 1985a.
97. Glazer, W.M.; Moore, D.C.; Bowers, M.B.; Bunney, B.S.; and Roffman, M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology, 87:480-483, 1985b.
98. Glazer, W.M.; Moore, D.C.; Schooler, N.R.; Brenner, L.M.; and Morgenstern, H. Tardive dyskinesia: A discontinuation study. Archives of General Psychiatry, 41:623-627, 1984.
99. Glazer, W.M.; Morgenstern, H.; and Doucette, J.T. The prediction of chronic persistent versus intermittent tardive dyskinesia: A retrospective follow-up study. British Journal of Psychiatry, 158:822-828, 1991.
100. Glazer, W.M.; Morgenstern, H.; and Doucette, J.T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Journal of Clinical Psychiatry, 54(4):133-139, 1993.
101. Glazer, W.M.; Morgenstern, H.; Schooler, N.R.; Berkman, C.S.; and Moore, D.C. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry, 157:585-592, 1990.
102. Glazer, W.M.; Naftolin, F.; Morgenstern, H.; Barnea, E.R.; MacLusky, M.J.; and Brenner, L.M. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology, 10:345-350, 1985c.
103. Goff, D.C.; Midha, K.K.; Brotman, A.W.; McCormick, S.; Waites, M.; and Amico, E.T. An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of Clinical Psychopharmacology, 11:193-197, 1991.
104. Goldman, D. Treatment of phenothiazine-induced dyskinesia. Psychopharmacology, 47:271-272, 1976.
105. Greendyke, R.M.; Webster, J.C.; and Kim, J. Lack of efficacy of pindolol in tardive dyskinesia. [Letter] American Journal of Psychiatry, 145:1318-1319, 1988.
106. Gunne, L.M.; Haggstrom, J.E.; and Sjokvist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in the brain GABA synthesis. Nature, 309:347-349, 1984.
107. Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, DHEW Publication No. (ADM) 76-338, 1976. pp. 534-537.
108. Hay, D.P.; Hay, L.; Blackwell, B.; and Spiro, H.R. ECT and tardive dyskinesia. Journal of Geriatric Psychiatry and Neurology, 3:106-109, 1990.
109. Huang, C.C.; Wang, R.H.; Hasegawa, A.; and Alverno, L. Reserpine and alpha methyl dopa in the treatment of tardive dyskinesia. Psychopharmacology, 73:359-362, 1981.
110. Hughes, A.J. Botulinum toxin in clinical practice. Drugs, 48:888-893, 1994.
111. Hunter, R.; Earl, J.C.; and Thornicroff, S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proceedings of the Royal Society of Medicine, 57:758-762, 1964.
112. Hyde, T.; Hotson, J.R.; and Kleinman, J.E. Differential diagnosis of choreiform tardive dyskinesia. Journal of Neuropsychiatry, 3:255-268, 1991.
113. Izumi, K.; Tominaga, H.; Koja, T.; Nomoto, M.; Shimizu, T.; Sonoda, H.; Imamura, K.; Igata, A.; and Fukuda, T. Meclofenozate therapy in tardive dyskinesia: A preliminary report. Biological Psychiatry, 21:151-160, 1986.
114. Jackson-Lewis, V.; Przedborski, S.; Kostic, V.; Suber, F.; Fahn, S.; and Cadet, J.L. Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha-tocopherol in rat brain. Brain Research Bulletin, 26:251-258, 1991.
115. Jellinger, K. Neuropathological findings after neuroleptic long-term therapy. In: Roizin, L.; Shnaki, H.; and Grcevic, N., eds. Neurotoxicology. New York, NY: Raven Press, 1977. pp. 25-42.
116. Jeste, D.V.; Lohr, J.B.; Clark, K.; and Wyatt, R.J. Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology, 8(Suppl.):38-48, 1988.
117. Jeste, D.V.; Lohr, J.B.; Kaufmann, C.A.; and Wyatt, R.J. Pathophysiology of tardive dyskinesia: Evaluation of supersensitivity theory and alternative hypotheses. In: Casey, D.E., and Gardos, G., eds. Tardive Dyskinesia: From Dogma to Reason. Washington, DC: American Psychiatric Press, 1986. pp. 15-32.
118. Jeste, D.V.; Potkin, S.G.; Sinha, S.; Feder, S.; and Wyatt, R.J. Tardive dyskinesia: Reversible and persistent. Archives of General Psychiatry, 36(5):585-590, 1979.
119. Jeste, D.V., and Wyatt, R.J. In search of treatment for tardive dyskinesia: Review of the literature. Schizophrenia Bulletin, 5(2):251-293, 1979.
120. Jeste, D.V., and Wyatt, R.J. Therapeutic strategies against tardive dyskinesia: Two decades of experience. Archives of General Psychiatry, 39:803-816, 1982a.
121. Jeste, D.V., and Wyatt, R.J. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press, 1982b.
122. Johnson, D.A.W.; Pasterski, G.; Ludlow, J.M.; Street, K.; and Taylor, R.D.W. The discontinuation of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiatrica Scandinavica, 67:339-352, 1983.
123. Jolley, A.G.; Hirsch, S.R.; McRink, A.; and Manchanda, R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical outcome at one year. British Medical Journal, 298:985-990, 1989.
124. Junker, D.; Steigleider, P.; and Gattaz, W.F. Alpha-tocopherol in the treatment of tardive dyskinesia. [Letter] Clinical Neuropharmacology, 15(Suppl. 1, Pt. B):639, 1992.
125. Jus, A.; Jus, K.; and Fontaine, P. Long-term treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 40:72-77, 1979.
126. Kane, J.M. Tardive dyskinesia. In: Jeste, D.V., and Wyatt, R.J., eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Press, 1984. pp. 68-95.
127. Kane, J.M. Tardive dyskinesia: Epidemiological and clinical presentation. In: Bloom, F.E., and Kupfer, D.J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995. pp. 1485-1496.
128. Kane, J.M., and Marder, S.R. Pharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19(2):287-302, 1993.
129. Kane, J.M.; Rifkin, A.; Woerner, M.; Reardon, G.; Sarantakos, S.; Schiebel, D.; and Ramos-Lorennzi, J. Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry, 40:893-896, 1983.
130. Kane, J.M., and Smith, J.M. Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Archives of General Psychiatry, 39:473-481, 1982.
131. Kane, J.M.; Woerner, M.; and Lieberman, J.A. Tardive dyskinesia: Prevalence, incidence, and risk factors. Psychopharmacology, 2(Suppl.):72-78, 1985.
132. Kane, J.M.; Woerner, M.; and Lieberman, J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8(Suppl. 4):52-56, 1988.
133. Kane, J.M.; Woerner, M.; and Sarantakos, S. Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. Journal of Clinical Psychiatry, 47(Suppl. 5):30-33, 1986.
134. Kazamatsuri, H.; Chien, C.-P.; and Cole, J.O. Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Archives of General Psychiatry, 27:95-99, 1972a.
135. Kazamatsuri, H.; Chien, C.-P.; and Cole, J.O. Treatment of tardive dyskinesia: II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Archives of General Psychiatry, 27:100-103, 1972b.
136. Kazamatsuri, H.; Chien, C.-P.; and Cole, J.O. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry, 130:479-483, 1973.
137. Keegan, D.L., and Rajput, A.H. Drug-induced dystonia tarda: Treatment with L-dopa. Diseases of the Nervous System, 38:167-169, 1973.
138. Keepers, G.A., and Casey, D.E. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. American Journal of Psychiatry, 148:85-89, 1991.
139. Klawans, H.L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry, 130:82-86, 1973.
140. Klawans, H.L. Therapeutic approaches to neuroleptic-induced tardive dyskinesia. In: Yahr, M.D., ed. The Basal Ganglia. New York, NY: Raven Press, 1976. pp. 447-457.
141. Klawans, H.L., Jr.; Ilahi, M.M.; and Shenker, D. Theoretical implications of the use of L-dopa in parkinsonism. Acta Neurologica Scandinavica, 46:409-441, 1970.
142. Klawans, H.L.; Tanner, C.M.; and Barr, A. The reversibility of "permanent" tardive dyskinesia. Clinical Neuropsychopharmacology, 7:153-159, 1984.
143. Klawans, H.L.; Weiner, W.J.; and Nausieda, P.A. The effects of lithium on an animal model of tardive dyskinesia. Progress in Neuro-Psychopharmacology, 1:53-60, 1977.
144. Kleedorfer, B.; Lees, A.J.; and Stern, G.M. Buspirone in the treatment of levodopa-induced dyskinesias. Journal of Neurology, Neurosurgery and Psychiatry, 54(4):376-377, 1991.
145. Kleinman, I.; Schacter, D.; and Kouter, E. Informed consent and tardive dyskinesia. American Journal of Psychiatry, 146(7):902-904, 1989.
146. Klieser, E.; Lehman, E.; Kinzler, E.; Wurthman, C.; and Heinrick, K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology, 15:455-515, 1995.
147. Klugewicz, D.A.; Tracy, K.; Lafargue, T.; Goldman, J.; Sanfilipo, M.; Egan, M.F.; and Rotrosen, J. Effects of antioxidant treatment on the VCM syndrome. [Abstract] Society of Neuroscience Abstracts, 22:1921, 1996.
148. Kojima, T.; Yamauchi, T.; Miyasaka, M.; Koshino, Y.; Nakane, Y.; Takahashi, R.; Shimzono, Y.; and Yagi, G. Treatment of tardive dyskinesia with ceruletide: A double-blind, placebo-controlled study. Psychiatry Research, 43:129-136, 1992.
149. Kopala, L.C., and Honer, W.G. Schizophrenia and severe tardive dyskinesia responsive to risperidone. Journal of Clinical Psychopharmacology, 14:430-431, 1994.
150. Korsgaard, S. Baclofen (Lioresel) in the treatment of neuroleptic induced tardive dyskinesia. British Journal of Psychiatry, 129:114-119, 1976.
151. Korsgaard, S.; Noring, U.; and Gerlach, J. Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology, 39:803-816, 1984.
152. Kovacic, B.; LeWitt, P.; and Clark, D. Suppression of neuroleptic-induced persistent abnormal movement in Cebus apella monkeys by enantiomers of 3-PPP. Journal of Neural Transmission, 74:97-107, 1988.
153. Kruse, W. Persistent muscular restlessness after phenothiazine treatment: Report of 3 cases. American Journal of Psychiatry, 117:152-153, 1960.
154. Kurata, K.; Hosokawa, K.; and Koshino, Y. Treatment of neuroleptic induced tardive dyskinesia. Journal of Neurology, 215:295-298, 1977.
155. Kushnir, S.L., and Ratner, J.T. Calcium channel blockers for tardive dyskinesia in geriatric patients. American Journal of Psychiatry, 146:1218-1219, 1989.
156. Lam, L.C.W.; Chiu, H.F.K.; and Hun, S.F. Vitamin E in the treatment of tardive dyskinesia: A replication study. Journal of Nervous and Mental Disorders, 182:113-114, 1994.
157. Lamberti, J.S., and Bellnier, T. Clozapine and tardive dystonia. Journal of Nervous and Mental Disorders, 181:137-138, 1993.
158. Lang, A.E., and Marsden, C.D. Alpha-methyl-paratyrosine and tetrabenazine in movement disorders. Clinical Neuropharmacology, 5:375-387, 1982.
159. Levkovitch, Y.; Kronenberg, J.; Kayser, N.; Zvyagelski, M.; Gaoni, B.; and Gadoth, N. Clozapine for tardive dyskinesia in adolescents. Brain and Development, 17:213-215, 1995.
160. Leys, D.; Vermersch, P.; Comayras, S.; Goudemand, M.; and Caron, J. Diltiazem for tardive dyskinesia. Lancet, 1:250-251, 1988.
161. Lieberman, J.A.; Alvir, J.; and Mukherjee, S.J.M. Treatment of tardive dyskinesia with bromocriptine: A test of the receptor modification strategy. Archives of General Psychiatry, 46:908-913, 1989.
162. Lieberman, J.A.; Lesser, M.; Johns, C.; Pollack, S.; Saltz, B.; and Kane, J.M. Pharmacological studies of tardive dyskinesia. Journal of Clinical Psychopharmacology, 8(Suppl.):57-63, 1988a.
163. Lieberman, J.A.; Pollack, S.; Lesser, M.S.; and Kane, J.M. Pharmacological characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology, 8:254-260, 1988b.
164. Lieberman, J.A.; Saltz, B.L.; Johns, C.A.; Pollack, S.; Borensein, M.; and Kane, J.M. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158:503-510, 1991.
165. Lindenmayer, J.-P.; Gardner, E.; Goldberg, E.; Opler, L.A.; Kay, S.R.; Van Praag, H.M.; Weiner, M.; and Zukin, S. High dose naloxone in tardive dyskinesia. Psychiatry Research, 26:19-28, 1987.
166. Lohr, J.B.; Cadet, J.L.; Lohr, M.A.; Larson, L.; Wasli, E.; Wade, L.; Hylton, R.; Vidoni, C.; Jeste, D.V.; and Wyatt, R.J. Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanisms. Schizophrenia Bulletin, 14(2):291-296, 1988.
167. Lohr, J.B., and Caligiuri, M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 57:167-173, 1996.
168. Loonen, A.J.M.; Verwey, A.H.; Roels, P.R.; Van Bavel, L.P.; and Doorschot, C.H. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 12:39-42, 1992.
169. 2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology, 1:541-548, 1991.
170. Ludatscher, J.I. Stable remission of tardive dyskinesia by L-dopa. Journal of Clinical Psychopharmacology, 9:39-41, 1989.
171. Mao, C.C.; Cheney, D.C.; Marco, E.; Revuelta, A.; and Costa, E. Turnover times of gamma aminobutyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus, and substantia nigra: Effects of repeated administration of haloperidol. Brain Research, 132:375-399, 1977.
172. Marder, S.R.; Van Putten, T.; and Mintz, J. Low-and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome. Archives of General Psychiatry, 44:518-521, 1987.
173. Matsumoto, T.; Nakahara, T.; Uchimura, H.; Hirano, M.; Yokoo, H.; Nakamura, K.; and Oomagari, K. Effect of systemically administered caerulein on dopamine metabolism in rat brain. Brain Research, 324:195-199, 1984.
174. McClelland, H.A.; Dutta, D.; Metcalf, A.; and Kerr, T.A. Mortality and facial dyskinesia. British Journal of Psychiatry, 148:310-316, 1986.
175. McMillan, B.A. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission. Journal of Neural Transmission, 64:1-12, 1985.
176. Meco, G.; Bedini, L.; Bonifanti, V.; and Sonsini, U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: A single-blind crossover study versus placebo. Current Therapeutics Research, 46:876-883, 1989.
177. Meltzer, H.Y., and Luchins, D.J. Effect of clozapine in severe tardive dyskinesia: A case report. Journal of Clinical Psychopharmacology, 4:286-287, 1984.
178. Mena, M.A.; Garcia, M.J.; Tabernero, C.; Casarejos, M.J.; Pardo, B.; and Garcia, J. Effects of calcium antagonists on the dopamine system. Clinical Neuropharmacology, 18:410-426, 1995.
179. Moore, D.C., and Bowers, M.B. Identification of a subgroup of tardive dyskinesia patients by pharmacological probes. American Journal of Psychiatry, 137:1202-1205, 1980.
180. Morgenstern, H., and Glazer, W.M. Identifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Archives of General Psychiatry, 50:723-733, 1993.
181. Moss, L.E. Neppe, V.M.; and Drevets, W.C. Buspirone in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology, 13:204-209, 1993.
182. Nasrallah, H.A.; Dunner, F.J.; McCalley-Whitters, M.; and Smith, R.E. Pharmacological probes of neurotransmitter systems in tardive dyskinesia: Implications for clinical management. Journal of Clinical Psychiatry, 47:56-59, 1986.
183. Neppe, V.M. High dose buspirone in case of tardive dyskinesia. [Letter] Lancet, II:1458, 1989.
184. Newton, J.E.O.; Cannon, D.J.; Couch, L.; Fody, E.P.; McMillan, D.E.; Metzer, M.S.; Paige, S.R.; Reid, G.M.; and Summers, B.N. Effects of repeated drug holidays on serum haloperidol concentration, psychiatric symptoms, and movement disorders in schizophrenic patients. Journal of Clinical Psychiatry, 50:132-135, 1989.
185. Newton, R.E.; Maranycz, J.D.; Alderice, M.T.; and Napoliello, M.J. Review of the side effect profile of buspirone. American Journal of Medicine, 80(3, Suppl. B): 17-21, 1986.
186. Nielsen, E.B., and Lyon, M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (fluphenthixol) in rats. Psychopharmacology, 59:85-89, 1978.
187. Nishikawa, T.; Kaneda, W.; Uegaki, A.; Koga, I.; Uchida, Y.; and Tanaka, M. Respiratory dyskinesia: A variety of forms differentially diagnosed by using a spirograph. Clinical Neuropharmacology, 15:315-321, 1992.
188. Nishikawa, T.; Tanaka, M.; Tsuda, A.; Koga, I.; and Uchida, Y. Clonidine therapy for tardive dyskinesia and related syndromes. Clinical Neuropharmacology, 7(3):239-245, 1984.
189. Nishikawa, T.; Tanaka, M.; Tsuda, A.; Koga, I.; and Uchida, Y. Treatment of tardive dyskinesia with ceruletide. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 12(5):803-812, 1988.
190. Nutt, J.G. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology, 40:340-345, 1990.
191. O'Flannagan, P.M. Clonazepam in the treatment of drug-induced dyskinesia. British Medical Journal, 1:269-270, 1975.
192. Owens, D.G. Involuntary disorders of movement in chronic schizophrenia: The role of the illness and its treatment. In: Casey, D.E., ed. Research and Treatment. Berlin, Germany: Springer-Verlag, 1985. pp. 79-87.
193. Owens, D.G.; Johnstone, E.C.; and Frith, C.D. Spontaneous involuntary disorders of movement. Archives of General Psychiatry, 39:452-461, 1982.
194. Pai, B.N.; Janakiramaiah, N.; Gangadhar, B.N.; and Ravindranath, V. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biological Psychiatry, 36:489-491, 1994.
195. Pakkenberg, H., and Fog, R. Short-term effect of perphenazine evantoate on the rat brain. Psychopharmacologia, 40:165-169, 1974.
196. Pakkenberg, H.; Fog, R.; and Nikkantan, B. The long-term effect of perphenazine enanthate on the rat brain: Some metabolic and anatomic observations. Psychopharmacologia, 29:329-336, 1973.
197. Passaro, E.; Bebas, H.; Olendorf, W.; and Yamada, T. Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Research, 241:335-340, 1982.
198. Peet, M.; Laugharne, J.; Rangarajan, N.; and Reynolds, G.P. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. International Journal of Clinical Psychopharmacology, 8:151-153, 1993.
199. Perenyi, A.; Arato, M.; Bagdy, G.; Frecska, E.; and Szucs, R. Tiapride in the treatment of tardive dyskinesia: A clinical and biochemical study. Journal of Clinical Psychiatry, 46:229-231, 1985.
200. Rascol, O.; Fabre, N.; Blin, O.; Poulik, J.; Sabatini, U.; Senard, J.-M.; Ane, M.; Montastruc, J.-L.; and Rascol, A. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Movement Disorders, 9:437-440, 1994.
201. Reiter, S.; Adler, L.; Angrist, B.; Peselow, E.; and Rotrosen, J. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Journal of Clinical Psychiatry, 50:26-27, 1989.
202. Roberts, H.J. Perspective on vitamin E as therapy. Journal of the American Medical Association, 246(2):129-131, 1981.
203. Robinson, A.D.T., and McCreadie, R.G. The Nithsdale schizophrenia survey: V. Follow up of tardive dyskinesia at 31/2 years. British Journal of Psychiatry, 149:621-623, 1986.
204. Ross, J.L.; Mackenzie, T.B.; Hanson, D.R.; and Charles, C.R. Diltiazem for tardive dyskinesia. Lancet, 1:824-825, 1987.
205. Roxburgh, P.A. Treatment of persistent phenothiazine-induced oral dyskinesia. British Journal of Psychiatry, 116:277-280, 1970.
206. Sabria, J.; Pastor, C.; Clos, M.V.; and Badia, A. Involvement of different types of voltage-sensitive calcium channels in the presynaptic regulation of noradrenaline release in rat brain cortex and hippocampus. Journal of Neurochemistry, 64:2567-2571, 1995.
207. Sandyk, R., and Snider, S.R. Naloxone treatment of L-dopa induced dyskinesias in Parkinson's disease. [Letter] American Journal of Psychiatry, 143:118, 1986.
208. Schmidt, M.; Meister, P.; and Baumann, P. Treatment of tardive dyskinesia with vitamin E. European Psychiatry, 6:201-207, 1991.
209. Schonecker, M. Ein eigentumliches syndrom im oralen bereich bei megaphen applikation. [Letter] Nervenartz, 28:35, 1957.
210. Schrodt, G.R.; Wright, J.H.; Simpson, R.; Moore, D.P.; and Chase, S. Treatment of tardive dyskinesia with propranolol. Journal of Clinical Psychiatry, 43:328-331, 1982.
211. Schulz, S.C.; Mack, R.; Zborowski, J.; Morris, D.; Sebree, T.; and Wallin, B. Efficacy, safety and dose-response of three doses of sertindole and three doses of Haldol in schizophrenia patients. [Abstract] Schizophrenia Research, 18:133, 1996.
212. Sedman, G. Clonazepam in the treatment of tardive oral dyskinesia. [Letter] British Medical Journal, 2:583, 1976.
213. Seeger, T.F.; Seymour, P.A.; and Schmidt, A.W. (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology and Experimental Therapeutics, 275:101-113, 1995.
214. Seibyl, J.P.; Glazer, W.M.; and Innis, R.B. Serotonin function in tardive dyskinesia. Psychiatric Annals, 19:310-314, 1989.
215. Shriqui, C.L.; Bradwejn, J.; Annable, L.; and Jones, B.D. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. American Journal of Psychiatry, 149:391-393, 1992.
216. Simpson, G.; Lee, J.H.; and Shrivastava, R.K. Clozapine in tardive dyskinesia. Psychopharmacology, 56:75-80, 1978.
217. Singer, K., and Cheng, M.N. Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal, 4:22-25, 1971.
218. Singh, M.M.; Becker, R.E.; Pitman, R.K.; Nasrallah, H.A.; and Kal, H. Sustained improvement in tardive dyskinesia with diazepam: Indirect evidence for corticolimbic involvement. Brain Research Bulletin, 11:179-185, 1983.
219. Skirboll, L.R.; Grace, A.A.; Hommer, D.W.; Rehfeld, J.; Goldstein, M.; Hokfelt, T.; and Bunney, B.S. Peptide-monoamine coexistence: Studies of actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience, 6:2111-2124, 1981.
220. Small, J.G.; Milstein, V.; Marhenke, J.D.; Hall, D.D.; and Kellams, J.J. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis. Journal of Clinical Psychiatry, 48:263-267, 1987.
221. Smith, J.M., and Baldessarini, R.J. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry, 37:1368-1373, 1980.
222. Smith, J.S., and Kiloh, L.G. Six-month evaluation of thiopropazate hydrochloride in tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry, 42:576-579, 1979.
223. Smith, R.C.; Tamminga, C.A.; Harasgti, J.; Pandy, G.; and Davis, J. Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry, 134:763-768, 1977.
224. Soni, S.D.; Freeman, H.L.; and Hussein, E.M. Oxypertine in tardive dyskinesia: An 8-week controlled study. British Journal of Psychiatry, 144:48-52, 1984.
225. Spivak, B.; Schwartz, B.; Radwan, M.; and Weizman, A. Alpha-tocopherol treatment for tardive dyskinesia. Journal of Nervous and Mental Disease, 180:400-401, 1992.
226. Stahl, S.W.; Thornton, J.E.; Simpson, M.L.; Berger, P.A.; and Napolielle, M.S. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry, 20:888-983, 1985.
227. Stedman, T.J.; Whiteford, H.A.; Eyles, D.; Welham, J.L.; and Pond, S.M. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. Journal of Clinical Psychopharmacology, 11:43-47, 1991.
228. Stein, M.H. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. [Letter] American Journal of Psychiatry, 148:683, 1991.
229. 2 receptor antagonists. Psychopharmacology, 98:372-379, 1989.
230. Strauss, A. Oral dyskinesia associated with buspirone use in an elderly woman. Journal of Clinical Psychiatry, 49:322-323, 1988.
231. Suddath, R.L.; Straw, G.M.; Freed, W.J.; Bigelow, L.L.B.; Kirch, D.; and Wyatt, R.J. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacology, Biochemistry and Behavior, 39:743-745, 1991.
232. Tamminga, C.A.; Crayton, J.; and Chase, T. Improvement in tardive dyskinesia after muscimol therapy. Archives of General Psychiatry, 36:595-598, 1979.
233. Tamminga, C.A.; Thaker, G.K.; Moran, M.; Kakigi, T.; and Gao, X.-M. Clozapine in tardive dyskinesia: Observations from human and animal model studies. Journal of Clinical Psychiatry, 55(9, Suppl. B): 102-106, 1994.
234. Tarsy, D. History and definition of tardive dyskinesia. Clinical Neuropharmacology, 6(2):91-99, 1983.
235. Tarsy, D.; Granacher, R.; and Bralower, M. Tardive dyskinesia in young adults. American Journal of Psychiatry, 134:1032-1034, 1977.
236. Thaker, G.K.; Nguyen, J.A.; Strauss, M.E.; Jacobson, R.; Kaup, B.A.; and Tamminga, C.A. Clonazepam treatment of tardive dyskinesia: A practical GABA-mimetic strategy. American Journal of Psychiatry, 147:445-451, 1990.
237. Thaker, G.K.; Nguyen, J.A.; and Tamminga, C.A. Increased saccadic distractability in tardive dyskinesia: Functional evidence for subcortical GABA dysfunction. Biological Psychiatry, 1:49-59, 1988.
238. Thaker, G.K.; Tamminga, C.A.; Alphs, L.D.; Lafferman, J.; Ferraro, T.N.; and Hare, T.A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Archives of General Psychiatry, 44:522-529, 1987.
239. Tollefson, G.D.; Beasley, C.M.; and Tran, P.V. Olanzapine versus haloperidol: Results of the multicenter, international trial. [Abstract] Schizophrenia Research, 18:131, 1996.
240. Trugman, J.M.; Leadbetter, R.; Zalis, M.E.; Burgdorf, R.O.; and Wooten, G.F. Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis. Movement Disorders, 9:441-446, 1994.
241. Van Putten, T., and Marder, S.R. Low-dose treatment strategies. Journal of Clinical Psychiatry, 47(Suppl. 5):12-16, 1986.
242. Van Putten, T.; Wirshing, W.; and Marder, S. Tardive Meige's syndrome responsive to clozapine. Journal of Clinical Psychopharmacology, 10:381-382, 1990.
243. Waddington, J.L. Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: Implications for the concept of tardive dyskinesia. In: Winlow, W., and Markstein, R., eds. The Neurobiology of Dopamine Systems. Manchester, England: Manchester University Press, 1986. pp. 51-66.
244. Waddington, J.L. Tardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Human Psychopharmacology, 2:11-22, 1987.
245. Wirshing, W.C.; Freidenberg, D.L.; Cummings, J.L.; and Bartzokis, G. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced Parkinsonism. Journal of Clinical Psychiatry, 9:407-411, 1989.
246. Woerner, M.G.; Kane, J.M.; Lieberman, J.A.; Alvir, J.; Bergmann, K.J.; Borenstein, M.; Schooler, N.R.; Mukherjee, S.; Rotrosen, J.; and Rubenstein, M. The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology, 11:34-42, 1991.
247. Woerner, M.G.; Sheitman, B.S.; Lieberman, J.A.; and Kane, J.M. Tardive dyskinesia induced by risperidone? [Letter] American Journal of Psychiatry, 153:843, 1996.
248. Wojcik, J.D.; Falk, W.E.; Fink, J.S.; Cole, J.O.; and Gelenberg, A.J. A review of 32 cases of tardive dystonia. American Journal of Psychiatry, 148:1055-1059, 1991.
249. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(2):325-351, 1991.
250. Wyatt, R.J. Practical Psychiatric Practice: Clinical Interview Forms, Rating Scales and Patient Handouts. Washington, DC: American Psychiatric Press, 1995.
251. Yagi, G.; Takamuja, M.; Kauba, S.; and Kanijima, K. Mortality rates of schizophrenic patients with tardive dyskinesia during 10 years: A controlled study. Keio Journal of Medicine, 38:70-72, 1989.
252. Yassa, R. Tardive dyskinesia and anticholinergic drugs: A critical review of the literature. Encephale, 14:233-239, 1988.
253. Yassa, R., and Jeste, D.V. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bulletin, 18(4):701-715, 1992.
254. Yassa, R., and Nair, N.P.V. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatrica Scandinavica, 86:262-266, 1992.
255. Yassa, R.; Nair, N.P.V.; Iskandar, H.; and Schwartz, G. Factors in the development of severe forms of tardive dyskinesia. American Journal of Psychiatry, 147:1156-1163, 1990.